Eptinezumab (Vyepti) vs Fremanezumab (Ajovy)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: CGRP ligand · full Migraine pipeline

Eptinezumab (Vyepti)

Marketed by H. Lundbeck

Approved in Migrainemonoclonal antibody
Reliable signal

NCT02974153 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 1,121 participants. The hard clinical primary endpoint was met for both doses: monthly migraine days decreased by 8.2 days with 300 mg and 7.7 days with 100 mg versus 5.6 days with placebo, with both comparisons statistically significant (p<0.0001).

Next expected readout: March 2027 · NCT04965675 (registry estimate)

Reported efficacy

Change From Baseline in Monthly Migraine Days (Week 1-12): Change From Baseline in Monthly Migraine Days (Week 1-12): 300 mg ALD403 -8.2 Migraine Days (range -23 to 11) | 100 mg ALD403 -7.7 Migraine Days (range -22 to 10) | Placebo -5.6 Migraine Days (range -25 to 9) (met)

Result source: NCT02974153

Fremanezumab (Ajovy)

Marketed by Teva Pharmaceutical Industries and partners

Approved in Migraineantibody
Partial signal

NCT02638103 · Phase 3 · completed

This was a large, quadruple-masked rollover/extension study continuing participants from two prior fremanezumab randomized trials, with placebo-matched injections used to preserve masking across monthly and quarterly regimens. Its primary outcomes were descriptive safety measures, and the study did not report a formal placebo-controlled primary efficacy comparison, so it provides useful but limited evidence for fremanezumab.

Reported efficacy

Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug (Baseline (Day -28 to Day -1), up to Week 12): Change in monthly migraine days over 12 weeks: fremanezumab -2.5 vs placebo -1.4; LS mean difference -1.0 (95% CI -1.90 to -0.16), p=0.0210 (n=123 and 111) (CT.gov posted results). (met)

Result source: NCT04458857

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Eptinezumab (Vyepti)
Change From Baseline in Monthly Migraine Days (Week 1-12): 300 mg ALD403 -8.2 Migraine Days (range -23 to 11) | 100 mg ALD403 -7.7 Migraine Days (range -22 to 10) | Placebo -5.6 Migraine Days (range -25 to 9) NCT02974153 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change From Baseline in Monthly Migraine Days (Weeks 1-12) (Week 1-12): 300 mg ALD403 -4.3 Migraine Days (Standard Deviation 3.42) | 100 mg ALD403 -3.9 Migraine Days (Standard Deviation 3.23) | 30 mg ALD403 -4.1 Migraine Days (Standard Deviation 3.22) | Placebo -3.1 Migraine Days (Standard Deviation 3.7) NCT02559895 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Fremanezumab (Ajovy)
Change in monthly migraine days over 12 weeks (median): fremanezumab 675 mg quarterly -4.0 and 225 mg monthly -4.2 vs placebo -2.7; both p<0.0001 (Wilcoxon) (CT.gov posted results). NCT02629861 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change in monthly migraine days over 12 weeks: fremanezumab -2.5 vs placebo -1.4; LS mean difference -1.0 (95% CI -1.90 to -0.16), p=0.0210 (n=123 and 111) (CT.gov posted results). NCT04458857 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change in monthly headache days of at least moderate severity over 12 weeks (median): fremanezumab 675 mg quarterly -4.2 (n=375) and 675/225/225 mg monthly -4.5 (n=375) vs placebo -2.5 (n=371); LS mean difference from placebo -1.8 (95% CI -2.46 to -1.15) and -2.1 (95% CI -2.76 to -1.45), both p < 0.0001 (Wilcoxon) (CT.gov posted results). NCT02621931 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eptinezumab (Vyepti)'s landscape · Fremanezumab (Ajovy)'s landscape